Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24399780 | 0.76 | CYP2D6 (0.37) | RIPK1SMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL45354 | 0.74 | MEN1 (0.40) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL2119818 | 0.74 | MEN1 (0.40) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL12721861 | 0.74 | MEN1 (0.40) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL14151715 | 0.73 | RIPK1 (0.32) | RIPK1SMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL22294675 | 0.73 | RIPK1 (0.32) | RIPK1SMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL22903602 | 0.71 | TSHR (0.36) | RIPK1SMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL9701108 | 0.70 | TAAR1 (0.41) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL4265847 | 0.70 | MEN1 (0.38) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL28625822 | 0.69 | TSHR (0.37) | CYP3A4CYP2C19ALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065205-B2 | Immediate/delayed drug delivery | DRUG DELIVERY INTERNATIONAL LIMITED (GB) | 2021-07-20 | — | — | US | claimed |
| US-20190125679-A1 | IMMEDIATE/DELAYED DRUG DELIVERY | UNIVERSITY OF STRATHCLYDE (GB) | 2019-05-02 | — | — | US | claimed |
| EP-2542228-B1 | PULSATILE DRUG RELEASE | UNIV STRATHCLYDE (GB) | 2017-11-29 | — | — | EP | claimed |
| EP-2542227-B1 | IMMEDIATE/DELAYED DRUG DELIVERY | UNIV STRATHCLYDE (GB) | 2017-11-22 | — | — | EP | claimed |
| EP-2542226-B1 | DELAYED PROLONGED DRUG DELIVERY | UNIV STRATHCLYDE (GB) | 2017-11-22 | — | — | EP | claimed |
| US-9474719-B2 | Pulsatile drug release | UNIVERSITY OF STRATHCLYDE (GB) | 2016-10-25 | — | — | US | claimed |
| US-9283192-B2 | Delayed prolonged drug delivery | UNIVERSITY OF STRATHCLYDE (GB) | 2016-03-15 | — | — | US | claimed |
| US-20100144657-A1 | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | claimed |
| US-20250312396-A1 | Control of Cellular Redox Levels | MCKENNA ELIZABETH (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250114411-A1 | SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES | EVELO BIOSCIENCES INC (US) | 2025-04-10 | — | — | US | disclosed |
| US-12268718-B2 | Control of cellular redox levels | LABYRINTH HOLDINGS LLC | 2025-04-08 | — | — | US | disclosed |
| WO-2024197124-A9 | ARGININE VASOPRESSIN RECEPTOR (AVPR) ANTAGONISTS AND METHODS OF USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4404921-A1 | SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES | Evelo Biosciences, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20230355689-A1 | SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES | EVELO BIOSCIENCES, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-2983657-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | Numedii, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014165823-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | NUMEDII, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20100144657-A1 | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144657-A1 | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS | OPRM1, OPRK1, OPRD1 | RIPK1 3455/4885SMN1; SMN2 2559/4885MEN1 4878/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | RIPK1 225/4885SMN1; SMN2 882/4885MEN1 544/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | RIPK1 170/4885SMN1; SMN2 609/4885MEN1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.